Our corporate department advised Deciphex on a €15 million investment from Claret Capital Partners, Europe's largest independent growth debt fund manager.
This strategic financing will accelerate Deciphex's expansion in the United States and support the company's ambition to become the leading provider of histopathology reporting services in the UK by 2027.
Donal O'Shea, Founder and CEO of Deciphex said:
"This extended relationship with Claret Capital Partners provides us with the capital to execute on our most ambitious growth plans."
Joey Mason, Venture Partner at Claret Capital Partners, commented:
"We're delighted to be supporting Deciphex with this follow-on funding. Having partnered with the company since 2023, we have been really impressed by the team's strong execution skills in addressing the growing market demand for Deciphex’s solutions.”
Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Claret Capital Partners is Europe's largest independent growth debt fund manager. Since 2013, the Claret funds have backed over 190 SMEs in the technology, life sciences and climate tech sectors, from a wide range of geographies across Europe.
Our Corporate and Banking teams advising Deciphex included Gavin Lawlor, Daniel Hackett, Grace Connolly Gusmões, Orlagh Scollard, Michael Hanley, Danny Heffernan and Senan Ross.
